阿尔茨海默病重新定义?双重朊蛋白病,带来治疗思路的重生

2019-08-06 奇点网 奇点网

近期,诺奖得主Stanley B. Prusiner团队在《科学转化医学》杂志上发文[1],以最新技术检测了百余份人类大脑标本,发现阿尔茨海默病(AD)患者脑内存在β淀粉样蛋白和tau蛋白的朊病毒形式。而且奇怪的是,年轻患者脑内的tau朊病毒水平更高,40岁患者约是90岁患者脑内水平的32倍! 如果AD是一种双重朊蛋白病,病理进展由朊病毒导致,淀粉蛋白斑块和神经纤维缠结都只是朊病毒的“遗骸”

阿尔茨海默病,就是我们常称的老年性痴呆,这是一个千亿级别的市场,十分诱人,而且已20年来,缺乏治疗性新药了(PS:国内绿谷上市了一个新药)。尤其最近5年,大量基于Aβ,Tau靶点的创新药物,全部折戟沉沙,让人看不到曙光!见报道:屡败屡战的千亿级阿尔茨海默病的药企和临床数据解读。不少人怀疑:难道传统对阿尔茨海默病的认知与Aβ有关,难道根本机制是错的?

近期,诺奖得主Stanley B. Prusiner团队在《科学转化医学》杂志上发文[1],以最新技术检测了百余份人类大脑标本,发现阿尔茨海默病(AD)患者脑内存在β淀粉样蛋白和tau蛋白的朊病毒形式。而且奇怪的是,年轻患者脑内的tau朊病毒水平更高,40岁患者约是90岁患者脑内水平的32倍!

如果AD是一种双重朊蛋白病,病理进展由朊病毒导致,淀粉蛋白斑块和神经纤维缠结都只是朊病毒的“遗骸”,那么现有的治疗探索或许将迎来一次天翻地覆的变化

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

Stanley B. Prusiner

图源 | UCSF

在说这个研究之前,我们先来说说朊病毒吧。

估计大家都还记得当年那段谈牛色变的日子。疯牛病之可怕,在于它超强的传染力、顽强的生存力和难以检测的隐蔽性。这几点从科学家命名“朊病毒”这个单词开始就没太大变化。

作为生命科学界独树一帜的奇葩“生物”,朊病毒简直无敌了。首先它只是一团蛋白,只凭自身就能让正常蛋白病变,完全蔑视中心法则;其次朊病毒很难搞,它稳定得很难用常规方法破坏,甚至还能在环境中积累;最后,检测它很困难,潜伏期实在太长了。

1997年,Stanley B. Prusiner因对朊病毒和朊蛋白PrP的研究获得了诺贝尔生理学或医学奖。PrP即是疯牛病的罪魁祸首,它引起的其他疾病还包括在其他动物中的传染性海绵状脑病(TSEs),以及人类中的克雅氏病(CJD)。

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

朊病毒导致的海绵状大脑

图源 | wiki

但Prusiner认为,PrP不可能是唯一的朊病毒,肯定还有其他的朊病毒和相应的疾病存在。

比如说,神经退行性疾病

根据定义,朊病毒指的是由宿主编码的蛋白质的特殊构象,拥有自我繁殖能力[2]。那神经退行性疾病确实很可疑了,无论是AD的Aβ和tau,还是帕金森病的α-突触核蛋白,不就是瞎折叠、瞎增殖、瞎搞死脑细胞这么个套路么。

事实上,确实有不少研究做出结果,Aβ和tau蛋白可以在实验动物之间相互传染,所以科学家们也把AD叫成朊病毒样疾病。不过也是因为只在实验室里看到传染,现实中没病例,所以这个“样”字不好去掉。

临床证据很快就来了。

2016年前后,两个科研团队分别发现,接受过硬脑膜移植[3]和尸源生长激素治疗的患者,死后脑内出现了大量的Aβ沉淀。是当年的治疗,让他们被Aβ传染了。

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

tau蛋白

荧光染色真是人类科学史上的伟大发明!!

图源 | wiki

Prusiner提出的假设是,Aβ和tau蛋白实际上是两种朊病毒,AD是一种双重朊蛋白病,只是这两种朊病毒侵略性不算强、繁殖慢,所以疾病进展很慢罢了

为了验证这个假设,最直观的自然是直接计算一下这俩“病毒”的效价。放以前这是个不太可能的事儿。以前研究Aβ和tau蛋白扩散都是用动物模型,耗时很长,可能得几个月。在这个时间尺度上,量化是很难的。

这次,研究者用了一种新技术,能够在细胞中进行分析,短短三天就可以检测出朊病毒水平,使量化成为可能。

这个方法挺简洁的。先给细胞里的正常蛋白接上黄色荧光蛋白,正常情况下健康细胞会表现出均匀的淡黄色,但经过朊病毒感染,蛋白们就会异变结团,显微镜下可以看到明亮的黄色荧光斑。直接量化光斑的分布,就可以计算出病毒的活动强度了

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

过程

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

健康细胞(左) 朊病毒细胞(右)

研究者共取得了一百多份大脑样本,其中10份是非神经系统疾病死亡患者的空白对照,7份来自进行性核上性麻痹(PSP)患者,3份来自皮质基底膜变性(CBD)患者,37份来自散发性AD患者,47份来自家族性发病AD患者,3份来自脑淀粉样血管病(CAA)患者,8份来自多系统萎缩(MSA)患者。

这么说病名可能比较陌生,换个角度,PSP、CBD是tau蛋白病,CAA是Aβ病,AD两种病理蛋白都有,MSA则是α-突触核蛋白病(α-Syn)

把这些大脑样本制成匀浆分别检测三种蛋白朊病毒活性之后,结果倒是非常分明的。该是tau蛋白病,那么就只有tau朊病毒活性;该是Aβ病,就Aβ朊病毒活跃;AD两种朊病毒都有,除MSA之外谁也不干α-Syn朊病毒的事儿

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

PSP和CBD(蓝),散发AD(红),家族发病AD两类不同突变(橙、深蓝),散发CAA(紫),家族发病CAA(粉),对照(灰)

而且在检查其他干扰因素的时候,研究者们发现了一个很奇怪的事情。AD患者脑内朊病毒的活性,和患者的年龄是成反比的!也就是说死亡年纪越大,朊病毒反而更加不活跃。

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

左Aβ右tau

研究者也考虑到,这个差异可能和基因表达水平本身也是有关的,所以又分别检测了Aβ和tau蛋白的各种可溶、不可溶形式的水平。

Aβ的两种短肽和未经水解的APP蛋白,虽然幅度不大,但也是保持随年龄增长下降的

Tau蛋白就有意思了。

首先,总的可溶性tau蛋白水平和年龄没关系;其次,总不溶性tau蛋白随年龄增长增加;再次,tau朊病毒活性随年龄增长下降;最后,不溶性磷酸化tau蛋白(p-tau)——被认为与临床严重程度有关——随年龄增长下降

根据研究者的计算,tau朊病毒和p-tau的半衰期大概是十年。举个例子,一个40岁病死的人,脑内tau朊病毒的水平会是90岁死者的32倍。

《科学》子刊:颠覆认知!诺奖得主团队重新定义阿尔茨海默病为双重朊蛋白病,AD治疗或迎来大变革丨科学大发现

不可溶tau(上) p-tau(下)

这是啥意思呢?就是说啊,疾病进展这个事情,跟朊病毒活性关系比较大,和累积了多少神经纤维缠结可能没啥关系啊!

按这个道理,针对β淀粉蛋白斑块和神经纤维缠结的治疗就是……

把人类的数据和小鼠对比一下,结果也是很有意思的。研究者记录了两种AD小鼠模型的脑内情况,大致是这样的:小鼠6-9个月大时出现神经病理学症状,200-300天检测到朊病毒活性,390天左右开始出现淀粉蛋白斑块,732天时朊病毒活性仍在增强

就……我也不知道说啥。

总被AD震惊,实在是我们对AD太无知。不说别的,研究得最深的这两种蛋白,至今功能仍有争议,特别是Aβ的作用,众说纷纭。有的研究者认为,Aβ的沉积根本无关紧要;有的研究者认为,可溶性Aβ具有一定的毒性;有的研究者认为,Aβ问题在引发tau蛋白的错误折叠。

各有各的说法,也各有各的支持依据。

那么我们能做的,也就是随时被颠覆认知的准备了。

回应学术争议的时候,Prusiner常引用神经科学家Bernard Katz的一句话:“有种科学家,如果有得选,宁愿用同事的牙刷也不用他的术语!”[4]

希望你们也永远不要被定义。

编辑神叨叨

我就在想啊,朊病毒这么牛逼,甚至能有病死动物→土壤→植物→其他动物这种传播途径,一般般的理化条件变化都搞不死,你们说再过个多少年,会不会土壤水源大面积被朊病毒污染呢……想到了不少废土文学……

这就是另一个科幻恐怖故事了

参考资料:

[1] Aoyagi A, Condello C, Stöhr J, et al. Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain[J]. Science translational medicine, 2019, 11(490): eaat8462.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1816934, encodeId=e9951816934e6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Oct 20 05:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006886, encodeId=9c6d20068863f, content=<a href='/topic/show?id=66b660e10b7' target=_blank style='color:#2F92EE;'>#朊蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60710, encryptionId=66b660e10b7, topicName=朊蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqTLTjicBiccpdUyHMGZV43nOBI6QIQqxVcy2EzXz67E390Q5j0R7QWjym391HxsyiaYt7NzbrcojRDw/132, createdBy=64462500151, createdName=ms705947299214030, createdTime=Thu Feb 20 01:27:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817957, encodeId=1bb2181e95727, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 20 09:27:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949317, encodeId=3017194931e78, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Oct 13 07:27:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470311, encodeId=429114e03112a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Aug 08 00:27:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370853, encodeId=92c53e085337, content=向科研人员致敬!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Tue Aug 06 10:39:27 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
    2019-08-06 坚强007

    向科研人员致敬!!!

    0

相关资讯

Ann Neurol:胰淀素作为2型糖尿病和阿尔茨海默病之间的潜在联系

由此可见,胰腺β细胞中的tau和Aβ包涵体以及脑中胰淀素沉积物的存在为T2DM和AD发病机制潜在重叠提供了新的证据。

Hypertension:抗高血压治疗可有效增加老年痴呆患者的脑血流量

脑血管变化,包括脑血流量(CBF)减少,发生在阿尔茨海默病的早期发展,并可能加快疾病的进展。在阿尔茨海默病早期,会发生脑血管变化,包括脑血流量(CBF)减少;脑血管变化可能会加速病程进展。研究人员开展一随机、双盲、安慰剂为对照的研究,调查用钙拮抗剂尼瓦地平(nilvadipine)治疗6个月是否会影响轻中度阿尔兹海默病患者的CBF。将58位患者随机分至两组(各29位),各组分别有22位符合要求并完

JAHA:尼伐地平降低轻度至中度阿尔茨海默病患者的血压但不会增加直立性低血压的患病率

由此可见,该研究表明开始低剂量的抗高血压治疗并不会显著增加轻度至中度阿尔茨海默病患者的OH风险。

屡败屡战的千亿级阿尔茨海默病的药企和临床数据解读

2016年11月,礼来Solanezumab宣布未能达到Ⅲ期临床试验主要临床终点; 2018年1月,武田制药宣布吡格列酮的阿尔茨海默病Ⅲ期临床试验失败; 2018年1月,辉瑞宣布放弃阿尔茨海默病领域的阿药物研发; 2018年2月,默沙东宣布停止Verubecestat的临床试验; 2018年6月,礼来与阿斯利康联合开发的lanabecestatⅢ期临床中止; 2019年1月,罗氏宣布

当他们找不到回家的路:阿尔茨海默病患者走失调查

我国轻度痴呆症患者的就诊率为14%,中度痴呆症患者的就诊率为25%,重度痴呆症患者的就诊率为34%。每一位失智走失老人的背后,都写满了整个家庭的离合悲欢。他们有的在久别重逢后痛哭拥抱,哭诉着以为再也见不到的恐惧和辛酸;也有的在一次次辨认否认后黯然神伤,终究盼不到虚惊一场的惊喜。

Hypertension:尼伐地平对阿尔茨海默病患者脑血流量的影响

总之,尼伐地平降低血压并增加海马中的CBF,而其他区域显示CBF稳定或非显著性的增加。这些发现不仅表明阿尔茨海默病患者保留的脑自动调节,而且还提示抗高血压治疗的有益脑血管效应。